Is There a “Best” Choice of Second-Line Agent in the Treatment of Recurrent, Potentially Platinum-Sensitive Ovarian Cancer?
- 1 March 2002
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 20 (5) , 1158-1160
- https://doi.org/10.1200/jco.2002.20.5.1158
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Randomized Controlled Trial of Single-Agent Paclitaxel Versus Cyclophosphamide, Doxorubicin, and Cisplatin in Patients With Recurrent Ovarian Cancer Who Responded to First-Line Platinum-Based RegimensJournal of Clinical Oncology, 2002
- Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus TopotecanJournal of Clinical Oncology, 2001
- Carboplatin Alone vs Carboplatin plus Epidoxorubicin as Second-Line Therapy for Cisplatin- or Carboplatin-Sensitive Ovarian CancerGynecologic Oncology, 2001
- Paclitaxel vs Epidoxorubicin plus Paclitaxel as Second-Line Therapy for Platinum-Refractory and -Resistant Ovarian CancerGynecologic Oncology, 1999
- ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancerThe Lancet, 1998
- BAD partly reverses paclitaxel resistance in human ovarian cancer cellsOncogene, 1998
- BAX enhances paclitaxel-induced apoptosis through a p53-independent pathwayProceedings of the National Academy of Sciences, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Bcl-2 family proteins: regulators of chemoresistance in cancerToxicology Letters, 1995
- Cancer of the OvaryNew England Journal of Medicine, 1993